Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2007-07-08
2008-10-28
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C530S351000, C530S402000
Reexamination Certificate
active
07442371
ABSTRACT:
Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5547933 (1996-08-01), Lin
patent: 7141547 (2006-11-01), Rosen et al.
patent: WO-01/79271 (2001-10-01), None
patent: WO-01/79442 (2001-10-01), None
Mikayama et al. Proc. Natl. Acad. Sci. USA vol. 90, pp. 10056-10060.
Voet et al. Biochemistry John Wiley & Sons, Inc., pp. 126-128 and 228-234.
Pennathur-Das et al., “Evidence for the Presenece of CFU-E with Increased In-Vitro Sensitivity to Erythropoietin in Sickle Cell Anemia”, Blood,vol. 63,No. 5, 1984: pp. 1168-1171.
Tong et al., “Formation of Erythrocyte Membrane Proteins during Erythropoietin-induced Differentiation”, Journal of Biological Chemistry, vol. 256,No. 24,1981, pp. 12666-12672.
Lin et al., “Cloning and Expression of the Human Erythropoietin Gene”, Proc. Natl. Acad. Sci. USA, vol. 82, 1985, pp. 7580-7584.
Morgan et al., “Erythropoietin and Renal Function in Sickle-Cell Disease”, British Medical Journal, vol. 285, 1982, pp. 1686-1688.
Korhonen et al., “Expression of bovine P-lactoglobulinhuman erythropoietin fusion protein in the milk of transgenic mice and rabbits”, Eur. J. Biochem. (1997), vol. 245, p. 482-489.
Fu Yan
Yu Zailin
Li Yi
Mertz Prema
LandOfFree
Recombinant human albumin-erythropoietin fusion proteins... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant human albumin-erythropoietin fusion proteins..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant human albumin-erythropoietin fusion proteins... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4018579